Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
ADC Therapeutics SA (ADCT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: ADCT (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit 69.35% | Avg. Invested days 24 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 133.76M USD | Price to earnings Ratio - | 1Y Target Price 8.2 |
Price to earnings Ratio - | 1Y Target Price 8.2 | ||
Volume (30-day avg) 352016 | Beta 1.52 | 52 Weeks Range 1.28 - 5.38 | Updated Date 04/1/2025 |
52 Weeks Range 1.28 - 5.38 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.62 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-03-27 | When - | Estimate -0.4117 | Actual -0.29 |
Profitability
Profit Margin -222.83% | Operating Margin (TTM) -191.82% |
Management Effectiveness
Return on Assets (TTM) -24.13% | Return on Equity (TTM) -705.53% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 325987168 | Price to Sales(TTM) 2.03 |
Enterprise Value 325987168 | Price to Sales(TTM) 2.03 | ||
Enterprise Value to Revenue 0.23 | Enterprise Value to EBITDA -1.43 | Shares Outstanding 99083800 | Shares Floating 73056495 |
Shares Outstanding 99083800 | Shares Floating 73056495 | ||
Percent Insiders 20.14 | Percent Institutions 61.64 |
Analyst Ratings
Rating 4.43 | Target Price 8.4 | Buy 2 | Strong Buy 4 |
Buy 2 | Strong Buy 4 | ||
Hold 1 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
ADC Therapeutics SA
Company Overview
History and Background
ADC Therapeutics SA is a commercial-stage biotechnology company specializing in antibody drug conjugates (ADCs) for the treatment of hematological malignancies and solid tumors. Founded in 2011, it has focused on developing proprietary ADCs targeting unmet medical needs.
Core Business Areas
- Oncology Therapeutics: Develops and commercializes antibody-drug conjugates (ADCs) for cancer treatment.
- Research and Development: Engages in research and development of new ADC candidates and platform technologies.
Leadership and Structure
The leadership team consists of experienced professionals in oncology drug development and commercialization. The organizational structure includes research, development, clinical, and commercial functions.
Top Products and Market Share
Key Offerings
- Zynlonta (loncastuximab tesirine-lpyl): Zynlonta is an ADC approved for relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The market for relapsed/refractory DLBCL is competitive. Key competitors include therapies from MorphoSys/Incyte (Monjuvi), Polivy (polatuzumab vedotin) from Roche/Genentech, and CAR-T cell therapies from Gilead (Yescarta) and Novartis (Kymriah). Revenue from Zynlonta are public knowledge through company reports.
- Camidanlumab tesirine: An ADC being evaluated in clinical trials for relapsed or refractory Hodgkin lymphoma. Competitors include brentuximab vedotin (Adcetris) from Takeda/Seagen and checkpoint inhibitors such as Keytruda and Opdivo. The market share and user base can be calculated after it gets approved.
Market Dynamics
Industry Overview
The oncology therapeutics market is large and growing, driven by aging populations and increasing cancer incidence. ADCs are a rapidly growing segment within oncology.
Positioning
ADC Therapeutics is positioned as a leader in the ADC space, with a focus on developing novel and differentiated therapies. Its competitive advantage lies in its proprietary ADC technology platform.
Total Addressable Market (TAM)
The total addressable market for ADCs in oncology is estimated to be billions of dollars annually. ADC Therapeutics is targeting specific segments within this market, such as DLBCL and Hodgkin lymphoma. The market value can be more precise if you define it to one product and the disease it has been granted to treat.
Upturn SWOT Analysis
Strengths
- Approved product (Zynlonta)
- Proprietary ADC technology platform
- Experienced management team
- Robust pipeline of ADC candidates
Weaknesses
- Dependence on Zynlonta for revenue
- Limited commercial infrastructure
- High R&D expenses
- Competition from established pharmaceutical companies
Opportunities
- Expansion of Zynlonta into new indications
- Partnerships with larger pharmaceutical companies
- Development of next-generation ADC technologies
- Acquisition of complementary assets
Threats
- Clinical trial failures
- Regulatory setbacks
- Competition from other ADC developers
- Patent expirations
Competitors and Market Share
Key Competitors
- GILD
- MRTX
- TAK
- RHHBY
- INCY
- NVS
Competitive Landscape
ADC Therapeutics has a differentiated ADC technology platform, but faces competition from larger, more established pharmaceutical companies with greater resources and broader pipelines. Their competitive advantage lies in their ADC specific therapies.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by the development and approval of Zynlonta.
Future Projections: Future growth is expected to be driven by Zynlonta sales expansion, pipeline development, and potential partnerships. Analyst estimates are available from financial news providers.
Recent Initiatives: Recent initiatives include expanding the Zynlonta label, advancing pipeline programs, and exploring strategic partnerships.
Summary
ADC Therapeutics is a biotechnology company specializing in antibody-drug conjugates for cancer treatment. Zynlonta's approval marks a key milestone, while its ADC technology platform allows it to target unmet medical needs. It faces competition from established pharmaceutical companies in the dynamic oncology therapeutics market. Future growth depends on label expansion, pipeline development, and successful partnerships.
Similar Companies
GILD
Gilead Sciences Inc
GILD
Gilead Sciences Inc
INCY
Incyte Corporation
INCY
Incyte Corporation
NVS
Novartis AG ADR
NVS
Novartis AG ADR
TAK
Takeda Pharmaceutical Co Ltd ADR
TAK
Takeda Pharmaceutical Co Ltd ADR
Sources and Disclaimers
Data Sources:
- ADC Therapeutics SA Investor Relations
- SEC Filings
- Company Reports
- Analyst Estimates
Disclaimers:
This analysis is for informational purposes only and does not constitute investment advice. Market share data is based on estimates and may not be precise. Future results may differ materially from projections.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About ADC Therapeutics SA
Exchange NYSE | Headquaters - | ||
IPO Launch date 1979-03-16 | CEO & Director Dr. Ameet Mallik M.B.A., M.S. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 263 | Website https://www.adctherapeutics.com |
Full time employees 263 | Website https://www.adctherapeutics.com | ||
ADC Therapeutics SA focuses on advancing its proprietary antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product is ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The company is also seeking to continue expanding ZYNLONTA into international markets and into earlier lines of DLBCL and indolent lymphomas, including follicular lymphoma (FL) and marginal zone lymphoma (MZL) as a single agent and in combination through its LOTIS-5 confirmatory Phase 3 clinical trial and LOTIS-7 Phase 1b clinical trial, as well as through investigator-initiated trials (IITs). In addition, it is investigating a CD-22 targeted compound, ADCT-602 that is in a Phase 1/2 investigator-initiated study in relapsed or refractory B-cell acute lymphoblastic leukemia. Further, its clinical-stage pipeline consists of ADCT-601 (mipasetamab uzoptirine) targeting AXL as a single agent and/or in combination in sarcoma, pancreatic, and NSCLC, as well as pre-clinical stage pipeline includes a portfolio of next generation investigational ADCs targeting Claudin-6, NaPi2b, PSMA, and other undisclosed targets. The company was incorporated in 2011 and is headquartered in Epalinges, Switzerland.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.